natgillin/translations-raw huggingface dataset:
No data are available for children aged up to 11 years. 
Podatkov za otroke, stare do 11 let, ni na voljo.
Maintenance OCS (up to 10 mg per day prednisone equivalent) were allowed. 
Dovoljeni so bili vzdrževalni PKS (do 10 mg ekvivalenta prednizona na dan).
There are limited data available on the use of reslizumab in patients older than 75 years of age. 
Razpoložljivi podatki o uporabi reslizumaba pri bolnikih, starejših od 75 let, so omejeni.
There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of reslizumab in pregnant women. 
Podatkov o uporabi reslizumaba pri nosečnicah ni oziroma so omejeni (manj kot 300 izpostavljenih nosečnosti).
Reslizumab should not be used to treat acute asthma exacerbations. 
Reslizumab se ne sme uporabljati za zdravljenje akutnih poslabšanj astme.
Treatment duration CINQAERO is intended for long-term treatment. 
Trajanje zdravljenja Zdravilo CINQAERO je namenjeno dolgotrajnemu zdravljenju.
The safety and efficacy of CINQAERO in children and adolescents aged up to 17 years have not been established for the indication of CINQAERO. 
Pediatrična populacija Varnost in učinkovitost zdravila CINQAERO pri otrocih in mladostnikih, starih do 17 let, nista bili dokazani za indikacijo zdravila CINQAERO.
The volume (in mL) required from the vial(s) should be calculated as follows: 0.3 x patient body weight (in kg). 
Potrebno količino (v ml) iz vial(e) je treba izračunati kot je navedeno: 0,3 x bolnikova telesna masa (v kg).
The antibodies had no impact on clinical pharmacodynamics, efficacy or safety. 
Protitelesa niso vplivala na klinično farmakodinamiko, učinkovitost ali varnost.
There was no prior asthma exacerbation requirement for this study. 
Za to študijo ni bilo potrebno predhodno poslabšanje astme.
Improvements were noted in FEV1 at 4 weeks following the first dose of reslizumab. 
Izboljšanja so opazili za FEV1 v 4. tednu po prvem odmerku reslizumaba.
** The nominal volume of the vials (10 mL or 2.5 mL for each vial) has to be used. 
** Uporabiti je treba nominalen volumen vial (10 ml ali 2,5 ml za eno vialo).
*See subsection “Description of selected adverse reactions” below 
*glejte spodnje podpoglavje "Opis izbranih neželenih učinkov"
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 16 hours at 2 °C-8 °C, unless dilution has taken place in controlled and validated aseptic conditions. 
Če zdravilo ni uporabljeno takoj, so časi in pogoji shranjevanja zdravila pred uporabo odgovornost uporabnika in običajno ne trajajo dlje kot 16 ur pri 2 °C-8 °C razen če je razredčitev potekala v kontroliranih okoliščinah in validiranih aseptičnih pogojih.
Efficacy variablea 
Spremenljivka učinkovitostia
* This dosing scheme is based on a maximum dose of 3 mg/kg. 
* Ta režim odmerjanja temelji na največjem odmerku 3 mg/kg.
Results for FEV1, ACQ and AQLQ are shown in Table 5 below for the overall population, and subgroup GINA 4 and 5. 
Rezultati za FEV1, ACQ in AQLQ so prikazani v spodnji preglednici 5 za celotno populacijo in za podskupino GINA 4 in 5.
Afterwards, CINQAERO could be used during breast-feeding if appropriate. 
Kasneje se zdravilo CINQAERO med dojenjem lahko uporablja, če je primerno.
Sputum eosinophils were measured in a subset of 38 adult patients at the end of therapy. 
Eozinofilce v sputum so izmerili v podskupini 38-ih odraslih bolnikov ob koncu zdravljenja.
It is unknown whether reslizumab is excreted in human milk. 
Ni znano, ali se reslizumab izloča v materino mleko.
Your doctor or nurse will watch you closely for signs of a reaction. 
Vaš zdravnik ali medicinska sestra vas bosta natančno spremljala za pojav znakov reakcije.
The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP. 
● Načrt za obvladovanje tveganj (RMP) Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
CI = Confidence interval 
b IZ = interval zaupanja
Infusion time may vary depending on the total volume to be infused. 
Čas infundiranja se lahko razlikuje glede na skupno količino, ki jo je treba infundirati.
In case of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse effects and given appropriate symptomatic treatment. 
V primeru prevelikega odmerjanja se priporoča spremljanje bolnika zaradi pojava znakov ali simptomov neželenih učinkov ter ustrezno simptomatsko zdravljenje.
The solution for infusion is intended only for intravenous use after dilution and should be prepared using aseptic technique as follows: 
Raztopina za infundiranje se uporablja samo intravensko po razredčitvi in jo je treba pripraviti z uporabo aseptične tehnike kot sledi:
Available pharmacodynamic/toxicological data in animals have shown excretion of reslizumab in milk. 
Razpoložljivi farmakodinamični/toksikološki podatki pri živalih kažejo na izločanje reslizumaba v mleko.
Asthma exacerbations were evaluated only in the exacerbation studies (Studies I and II: reslizumab 
Poslabšanja astme so ocenili samo v študijah poslabšanja (študiji I in II: reslizumab
Eosinophils began to return towards baseline in those reslizumab patients completing a 90-day follow-up assessment (394 µL-1, n=36). 
Eozinofilci so se začeli vračati proti izhodišču pri tistih bolnikih na reslizumabu, ki so končali oceno po 90-dnevnem spremljanju (394 µl-1, n = 36).
The data did not indicate a difference in the safety profile of reslizumab in paediatric patients compared with that in adult patients. 
Podatki ne kažejo na razliko v varnostnem profilu reslizumaba pri pediatričnih bolnikih v primerjavi z odraslimi bolniki.
No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving reslizumab or the response to new immunisations in patients receiving reslizumab. 
Podatki o sekundarnem prenosu okužb z oseb, ki so bile cepljene z živimi cepivi, na bolnike, ki prejemajo reslizumab, ali o odzivu na novo imunizacijo pri bolnikih, ki prejemajo reslizumab, niso na voljo.
Table 1: Vial-based dosing scheme* for patients with body weight between 35 kg and 199 kg Body weight (kg) 
Preglednica 1: Režim odmerjanja na osnovi vial* za bolnike s telesno maso med 35 kg in 199 kg Telesna masa (kg)
Study III was a 16-week, randomised, placebo-controlled study. 
Študija III je bila 16-tedenska, randomizirana, s placebom nadzorovana študija.
Proteinaceous particles may be present in the concentrate that appear as translucent to white, amorphous particles, some of which may look fibrous. 
V koncentratu so lahko prisotni beljakovinski delci, ki se lahko pojavijo kot prosojni do beli, amorfni delci, med katerimi so lahko nekateri videti vlaknati.
The European Medicines Agency has deferred the obligation to submit the results of studies with CINQAERO in one or more subsets of the paediatric population in asthma (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom CINQAERO za eno ali več podskupin pediatrične populacije z astmo (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
The highest single dose administered intravenously was reported at 12.1 mg/kg and had no clinical consequences for the patient. 
Poročali so, da je bil največji intravenski enkratni odmerek 12,1 mg/kg in za bolnika ni imel kliničnih posledic.
Blood creatine phosphokinase elevations were transient and asymptomatic, and did not lead to treatment discontinuation. 
Zvečanja vrednosti kreatin fosfokinaze so bila prehodna in asimptomatska ter niso vodila v prekinitev zdravljenja.
If the solution for infusion has been stored in a refrigerator, allow it to reach room temperature (15 °C-25 °C). 
Če je bila raztopina za infundiranje shranjena v hladilniku, počakajte, da se ogreje na sobno temperaturo (15 °C - 25 °C).
The primary efficacy measure for both Studies I and II was the frequency of asthma exacerbations for each patient during the 52-week treatment period. 
Primarno merilo učinkovitosti za študiji I in II je bila pogostnost poslabšanja astme za vsakega bolnika v 52-tedenskem obdobju zdravljenja.
Experience in paediatric patients is limited (see section 5.1). 
Izkušnje pri pediatričnih bolnikih so omejene (glejte poglavje 5.1).
Peak serum concentrations of approximately 80 µg/mL are typically observed at the end of the infusion. 
Največje koncentracije v serumu približno 80 µg/ml so običajno opazili ob koncu infundiranja.
If patients become infected whilst receiving treatment with reslizumab and do not respond to anti-helminth treatment, temporary discontinuation of therapy should be considered. 
Če se bolniki okužijo med zdravljenjem z reslizumabom in se ne odzovejo na zdravljenje z antihelmintiki, je treba razmisliti o začasnem prenehanju zdravljenja.
Currently available data in adolescents from 12 to 17 years are described in sections 4.8, 5.1 and 5.2, but no recommendation on a posology can be made. 
Trenutno razpoložljivi podatki za mladostnike, stare od 12 do 17 let, so opisani v poglavjih 4.8, 5.1 in 5.2,
Reslizumab is an antibody with a molecular mass of 147 kDaltons and is therefore not expected to be excreted in urine. 
Reslizumab je protitelo z molekulsko maso 147 kDa, zato se ne pričakuje, da bi se izločal z urinom.
3 mg/kg [n=14] and placebo [n=11]). 
3 mg/kg [n = 14] in placebo [n = 11]).
As a precautionary measure, it is preferable to avoid the use of CINQAERO during pregnancy. 
Iz previdnostnih razlogov se je med nosečnostjo uporabi zdravila CINQAERO bolje izogibati.
Age, mean in years Asthma duration, mean in years 
Starost, povprečna v letih Trajanje astme,
Based on the similar reslizumab exposure observed in patients older than 65 years of age as compared to patients 18 to <65 years of age, no dose adjustment is recommended (see section 5.2). 
Na podlagi podobne izpostavljenosti reslizumabu, ki so jo opazili pri bolnikih, starejših od 65 let, v primerjavi z bolniki, starimi 18 do < 65 let, se prilagajanje odmerka ne priporoča (glejte poglavje 5.2).
Reslizumab is a humanised monoclonal antibody (IgG4, κ) against the human interleukin-5 (IL-5). 
Reslizumab je humanizirano monoklonsko protitelo (IgG4, κ) proti humanemu interlevkinu-5 (IL-5).
No direct effect of hepatic function on the pharmacokinetics of reslizumab is expected because antibodies are principally cleared by catabolism. 
Neposredni učinek delovanja jeter na farmakokinetiko reslizumaba se ne pričakuje, saj se protitelesa izločajo v glavnem s katabolizmom.
IL-5 is a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. 
IL-5 je ključni citokin, odgovoren za diferenciacijo, dozorevanje, novačenje in aktiviranje humanih eozinofilcev.
Overall population 
Celotna populacija
Following multiple doses, serum concentrations of reslizumab accumulate approximately 1.5- to 1.9-fold. 
Po večkratnih odmerkih se serumske koncentracije reslizumaba kopičijo približno 1,5- do 1,9-kratno.
Table 3 presents the demographics and baseline characteristics of Studies I, II and III. 
V preglednici 3 so predstavljene demografske in izhodiščne lastnosti za študije I, II in III.
As reslizumab binds to a soluble target, linear non-target-mediated clearance is expected. 
Ker se reslizumab veže na topno tarčo, se pričakuje linearen netarčno posredovani očistek.
Eosinophils may be involved in the immunological response to some helminth infections. 
Infestacije s paraziti (helminti) Eozinofilci so lahko vpleteni v imunski odziv na nekatere infestacije s helminti.
A double dose must not be administered to make up for a missed dose. 
Ni dovoljeno uporabiti dvojnega odmerka, da se nadomesti izpuščeni odmerek.
In Studies I and II only, patients were required to have at least one asthma exacerbation requiring systemic corticosteroid use in the year prior to study entry. 
Le v študijah I in II se je od bolnikov zahtevalo vsaj eno poslabšanje astme, ki je zahtevalo uporabo sistemskega kortikosteroida, v letu pred vstopom v študijo.
What you need to know before you are given CINQAERO You must not receive CINQAERO: 
Kaj morate vedeti, preden boste dobili zdravilo CINQAERO Zdravila CINQAERO ne smete prejeti:
(p<0.0001) a The values represent the treatment difference between placebo and reslizumab 3 mg/kg based on adjusted means over the specified time period for each treatment group, except for the change to week 16 for AQLQ, which was the first timepoint where AQLQ was assessed. 
(p < 0,0001) a Vrednosti predstavljajo razliko v zdravljenju med placebom in reslizumabom 3 mg/kg na podlagi prilagojenih povprečij v določenem časovnem obdobju za vsako skupino zdravljenja, razen za spremembo glede na 16. teden za AQLQ, ki je bila prva časovna točka za oceno AQLQ.
Patients with pre-existing helminth infections should be treated before starting reslizumab therapy. 
Bolnike z obstoječimi infestacijami s helminti je treba zdraviti pred uvedbo zdravljenja z reslizumabom.
Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment. 
Bolnikom je treba naročiti, naj takoj poiščejo zdravniško pomoč, če astma po uvedbi zdravljenja ostane neurejena ali se poslabša.
Other medicines and CINQAERO 
Druga zdravila in zdravilo CINQAERO
Reslizumab has a volume of distribution of approximately 5 L, suggesting minimal distribution to the extravascular tissues. 
Reslizumab ima volumen porazdelitve približno 5 l, kar kaže na minimalno porazdelitev v ekstravaskularna tkiva.
Talk to your doctor or nurse before you are given CINQAERO: - if you have a parasitic infection or if you live in an area where parasitic infections are common or if you are travelling to such a region, as this medicine may weaken your body's ability to fight certain types of parasitic infections. 
- če imate okužbo s paraziti ali živite v območju, kjer so okužbe s paraziti pogoste, ali če na tako področje potujete, saj lahko to zdravilo oslabi sposobnost telesa, da se bori proti nekaterim vrstam okužb s paraziti.
It may take more than one dose before your asthma symptoms improve. 
Morda bo za izboljšanje simptomov astme potreben več kot en odmerek.
If a reslizumab infusion is missed on the planned date, dosing should resume as soon as possible on the indicated dose and regimen. 
Izpuščeni odmerek Če je na načrtovani dan infuzija reslizumaba izpuščena, je treba z odmerjanjem nadaljevati čim prej z navedenim odmerkom in režimom.
Due to an overlap in signs and symptoms, it was not possible to distinguish between an anaphylactic reaction, another hypersensitivity reaction and an infusion-related reaction in all cases (see section 4.4). 
Zaradi prekrivanja znakov in simptomov v vseh primerih ni bilo možno razločevati med anafilaktično reakcijo, drugo preobčutljivostno reakcijo in reakcijo, povezano z infuzijo (glejte poglavje 4.4).
Reslizumab has not been studied in patients receiving live vaccines. 
Reslizumaba niso preučili pri bolnikih, ki so prejeli živa cepiva.
Reslizumab has a half-life of about 24 days. 
Reslizumab ima razpolovni čas približno 24 dni.
Tell your doctor or nurse straight away if you have any of the symptoms of an allergic reaction (e.g. itching, trouble breathing, wheezing, fever, shivering, dizziness, headache, nausea, vomiting, abdominal discomfort, skin rash, redness or swelling). 
Zdravniku ali medicinski sestri takoj povejte, če imate katerega od simptomov alergijske reakcije (npr. srbenje, težave z dihanjem, sopenje, zvišana telesna temperatura, tresenje, omotica, glavobol, siljenje na bruhanje, bruhanje, nelagodje v trebuhu, kožni izpuščaj, rdečina ali oteklost).
In this study, the percentage of sputum eosinophils was reduced from a mean baseline value of 17.4% (standard deviation: 15.9%) by 82% at end of therapy in the reslizumab group. 
V tej študiji se je odstotek eozinofilcev v sputumu zmanjšal od povprečne izhodiščne vrednosti 17,4 % (standardni odklon: 15,9 %) za 82 % ob koncu zdravljenja v skupini z reslizumabom.
Your doctor or nurse will watch you closely during and after your infusion for signs of an allergic reaction. 
Vaš zdravnik ali medicinska sestra vas bosta med infundiranjem in po njem skrbno spremljala zaradi pojava znakov alergijske reakcije.
Reslizumab has not been studied in patients concurrently taking immunosuppressant medicinal products other than oral corticosteroids (OCS); therefore, the safety and efficacy profile of reslizumab in these patients is unknown. 
Reslizumaba niso preučili pri bolnikih, ki sočasno jemljejo imunosupresivna zdravila, razen peroralnih kortikosteroidov (PKS), zato je profil varnosti in učinkovitosti reslizumaba pri teh bolnikih neznan.
It must not be administered by the subcutaneous, oral or intramuscular route. 
Ne sme se uporabljati subkutano, peroralno ali intramuskularno.
Eosinophils are white blood cells involved in asthma inflammation. 
Eozinofilci so bele krvne celice, ki so vpletene v astmatsko vnetje.
Based on the characteristics of reslizumab, drug-drug interactions are not expected. 
Na podlagi značilnosti reslizumaba se medsebojno delovanje z zdravili ne pričakuje.
It is unlikely that CINQAERO will affect your ability to drive and use machines. 
Ni verjetno, da bi zdravilo CINQAERO vplivalo na vašo sposobnost vožnje ali upravljanja strojev.
Uncommon (may affect up to 1 in 100 people) • Muscle pain (myalgia). 
Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov) • bolečine v mišicah (mialgija)
If an anaphylactic reaction occurs, administration of reslizumab should be stopped immediately and appropriate medical treatment should be provided; reslizumab must be discontinued permanently (see section 4.3). 
Če se pojavi anafilaktična reakcija, je treba dajanje reslizumaba takoj ustaviti in nuditi ustrezno zdravljenje; zdravljenje z reslizumabom je treba trajno prekiniti (glejte poglavje 4.3).
The reduction in blood eosinophil counts by reslizumab in anti-reslizumab antibody-positive patients was not different from patients who were anti-reslizumab antibody-negative. 
Zmanjšanje števila eozinofilcev v krvi z reslizumabom, se pri bolnikih, pozitivnih na protitelesa proti reslizumabu, ni razlikovalo od tistega pri bolnikih, ki so bili negativni na protitelesa proti reslizumabu.
If you stop using CINQAERO 
Če ste prenehali uporabljati zdravilo CINQAERO
Asthma exacerbation ratea 
Stopnja poslabšanja astmea
CINQAERO should be prescribed by physicians experienced in the diagnosis and treatment of the above-mentioned indication (see section 4.1). 
Zdravilo CINQAERO mora predpisati zdravnik z izkušnjami v diagnostiki in zdravljenju zgoraj navedene indikacije (glejte poglavje 4.1).
The pharmacokinetics of reslizumab was similar in adults (18-65 years of age; n=759) and elderly patients (greater than 65 years of age; n=30). 
Farmakokinetika reslizumaba je bila pri odraslih (starih 18 do 65 let; n = 759) in starejših bolnikih (starih več kot 65 let; n = 30) podobna.
Results of population pharmacokinetic analysis confirm that concomitant use of either leukotriene antagonists or systemic corticosteroids does not affect the pharmacokinetics of reslizumab (see section 5.2). 
Rezultati analize populacijske farmakokinetike potrjujejo, da sočasna uporaba antagonistov levkotrienskih receptorjev ali sistemskih kortikosteroidov ne vpliva na farmakokinetiko reslizumaba (glejte poglavje 5.2).
The malignancies observed in reslizumab-treated patients were diverse in nature and without clustering of any particular tissue type. 
Malignosti, ki so jih opazili pri bolnikih, zdravljenih z reslizumabom, so bile različne in brez kopičenja primerov za določeno tkivo.
CINQAERO must not be administered as a bolus injection or as undiluted concentrate. 
CINQAERO se ne sme dati kot bolusna injekcija ali kot nerazredčen koncentrat.
Decreases in blood eosinophils were related to reslizumab levels. 
Zmanjšanja eozinofilcev v krvi so bila povezana z ravnmi reslizumaba.
The effect of reslizumab 3 mg/kg administered once every 4 weeks on secondary endpoints, including FEV1, Asthma Quality of Life Questionnaire (AQLQ), Asthma Control Questionnaire (ACQ) and Asthma Symptom Utility Index (ASUI), further supports the efficacy of reslizumab 3 mg/kg compared to placebo. 
Učinek reslizumaba 3 mg/kg, danega enkrat na 4 tedne ob sekundarnih opazovanih dogodkih, vključno z FEV1, Vprašalnikom o kakovosti življenja bolnikov z astmo (AQLQ-Asthma Quality of Life Questionnaire), Vprašalnikom o urejenosti astme (ACQ-Asthma Control Questionnaire) in Indeksom uporabnosti pri simptomih astme (ASUI-Asthma Symptom Utility Index) nadalje podpira učinkovitost reslizumaba 3 mg/kg v primerjavi s placebom.
Posology CINQAERO is given as intravenous infusion once every four weeks. 
Odmerjanje Zdravilo CINQAERO se daje kot intravenska infuzija enkrat na štiri tedne.
These reactions were observed during or within 20 minutes after completion of the reslizumab infusion and were reported as early as the second dose of reslizumab. 
Te reakcije so opazili med infundiranjem reslizumaba ali v 20 minutah po infundiranju, o njih pa so poročali že ob drugem odmerku reslizumaba.
Reslizumab binds human IL-5 with picomolar affinity blocking its biological function; consequently survival and activity of eosinophils are reduced. 
Reslizumab veže humani IL-5 s pikomolarno afiniteto in zavre njegovo biološko funkcijo; posledično se zmanjšata preživetje in aktivnost eozinofilcev.
No physical or biochemical compatibility studies have been conducted to evaluate the co-administration of reslizumab with other medicinal products. 
Študij fizikalne ali biokemične združljivosti za ocenjevanje sočasne uporabe reslizumaba z drugimi zdravili niso izvedli.
These adverse reactions were observed during or within 20 minutes after completion of the infusion. 
Te neželene učinke so opazili med infundiranjem ali v 20 minutah po koncu infundiranja.
The range of systemic exposures in patients from 12 to less than 18 years of age (n=15) overlapped that in the other groups although the median value was slightly lower than in adult patients (18-65 years of age; n=759) and elderly patients (greater than 65 years of age; n=30). 
Razpon sistemske izpostavljenosti pri bolnikih, starih od 12 do manj kot 18 let (n = 15), se je prekrival s tistim pri drugih skupinah, čeprav je bila mediana vrednosti nekoliko manjša kot pri odraslih bolnikih (starih 18 do 65 let; n = 759) in starejših bolnikih (starih več kot 65 let; n = 30).
Interleukin-5 is a protein your body makes that plays a key role in inflammation in asthma by activating eosinophils. 
Interlevkin-5 je beljakovina, ki jo telo proizvaja in ima odločilno vlogo pri astmatskem vnetju z aktiviranjem eozinofilcev.
The solution for infusion should not be infused concomitantly in the same intravenous line with other medicinal products. 
Raztopine za infundiranje ne infundirajte sočasno z drugimi zdravili skozi isto intravensko linijo.
CINQAERO is a medicine containing the active substance reslizumab, a monoclonal antibody, a type of protein that recognises and binds to a specific target substance in the body. 
Zdravilo CINQAERO vsebuje učinkovino reslizumab, monoklonsko protitelo, ki je vrsta beljakovine, ki v telesu prepoznava specifične ciljne snovi in se nanje veže.
You will be given CINQAERO by a doctor or nurse as an infusion (drip) into a vein. 
Zdravilo CINQAERO vam bo dal zdravnik ali medicinska sestra v obliki infuzije (kapanja) v žilo.
Proportions of patients in GINA steps 4 and 5c 
Delež bolnikov s 4. in 5. korakom po GINAc
CINQAERO reduces how often you have flare-ups of your asthma, helps you breathe better and decreases your asthma symptoms. 
Zdravilo CINQAERO zmanjša pogostnost poslabšanja astme, izboljša dihanje in zmanjša simptome astme.
CINQAERO blocks interleukin-5 activity and reduces the number of eosinophils in your blood and lungs. 
Zdravilo CINQAERO zavira aktivnost interlevkina-5 in zmanjša število eozinofilcev v krvi in pljučih.